Diagnósticos da América (DASA3) Q3 2025 earnings summary

Executive summary

• Achieved strong operational and financial results in Q3 2025, with national leadership in diagnostics, driven by disciplined execution, productivity, digitalization, and a strengthened management team.

• Completed segregation of most hospital assets and reinforced focus on diagnostics, supported by divestments totaling R$704.8 million, resulting in the lowest leverage since 2021.

• Continued innovation with 80 new services launched in 2024 and increased use of AI to optimize patient journey and operational efficiency.

• Net income for Q3 2025 reached R$97 million, reversing a loss of R$87 million in Q3 2024, with a net margin of 3.1%.

• Rede Américas, the new joint venture, showed consistent improvement in key performance indicators.

Financial highlights

• Consolidated gross revenue was R$2.9 billion in Q3 2025, with diagnostics revenue up 12% year-over-year and hospitals/oncology in the northeast up 7%.

• Gross margin improved by 5.0 percentage points to 33.8%, and EBITDA margin expanded by 7.6 percentage points to 26.5%.

• Operational cash generation was R$481 million, up over 113% year-over-year, and free cash flow reached R$415 million, up 251%.

• Net income was R$97 million, reversing a prior loss, and net financial debt after acquisitions payable was R$6.66 billion, down 34%.

• Leverage ratio improved to 2.38x EBITDA, down from 4x at the start of the year.

Outlook and guidance

• Management remains focused on further margin expansion, operational efficiency, and disciplined capital allocation, with ongoing digitalization and process optimization.

• Continued discipline in execution and efficiency to deliver sustainable value and results.

• Positive outlook for premium and B2B segments, with market share gains anticipated.